SIGNANT HEALTH
THE EVIDENCE GENERATION COMPANY™

SmartSignals™ Solutions for COVID-19 Treatment

RELIABLE EVIDENCE GENERATION TO OPTIMIZE COVID-19 TREATMENT RESEARCH OUTCOMES

Whether you are investigating antivirals, cellular therapies, immunomodulators, neutralizing antibodies, or a combination of these, COVID-19 treatment studies are actively evolving and entail many unknowns.

Signant leverages experience, proven clinical research technology solutions, and deep scientific expertise to facilitate COVID-19 treatment study success.

ACCELERATE YOUR TREATMENT STUDIES

Researchers around the world are working at record speed to find new ways to treat and prevent COVID-19. Signant's eConsent, RTSM, and eCOA solutions speed up studies and increase data accuracy to help you reach conclusions about treatment efficacy faster.

SEIZE THE DATA

Access your study data when and how you need it. With our data management services, you can collect, review, clean, and migrate clinical data as your protocol requires. From audit trail logs to change authorizations and database locks/archiving, we help you seamlessly move between study phases following adaptive design decision points.

SIMPLIFY GLOBAL STUDIES

With participant populations and sites scattered around the globe, you will need tools and expertise to handle the logistics of a geographically dispersed study. We help manage complexities with solutions such as telemedicine, eCOA, and RTSM so you can focus on your study endpoints.

RETIRE PAPER PROCESSES

The coronavirus pandemic proved to our industry that pencil and paper are not conducive to decentralized, global trials. Signant's eConsent and eCOA reduce errors and increase data reliability in COVID-19 treatment studies. Combine them with RTSM and Telemedicine for fully digitized study processes that reduce burdens on sponsors, sites, and patients.

RELY ON SCIENCE & MEDICINE EXPERTS

Investigating COVID-19 treatments means navigating uncharted waters. Signant's science and medicine team can leverage experience in these studies to provide guidance on all areas of the development process. From decentralized designs to site monitoring and eCOA strategy, we help generate the accurate endpoint data you need for regulatory submission.

Managing COVID-19 in future depends on treatment research taking place today. Signant helps study teams generate accurate and reliable endpoint data through proven technology solutions and clinical operations expertise.

SIGNANT'S COVID-19 CLINICAL TRIAL EXPERIENCE

Phases

I II III IV



32
Languages



3,800+
Sites

44
Countries

54,000+
Patients

54
Trials

SMARTSIGNALS SOLUTIONS

The SmartSignals solutions can be used individually or integrated together for a seamless, end-to-end digital experience.

eCOA

Scientific Advisory

RTSM

eConsent

DISCUSS YOUR NEXT STUDY WITH US

Our global team of therapeutic area experts advise on all areas of the clinical development process, including:

- Clinical science and medicine
- Data analysis
- Regulatory
- Operations and trial administration
- Global logistics



MEET THE EXPERTS